Dr. Francis Collins led the U.S. National Institutes of Health (NIH), the world’s largest funder of biomedical research, ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

A groundbreaking effort is underway to bring back a long-lost predator using cutting-edge genetic technology. Scientists are ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

Somewhat predictably, EFSA found "no new potential hazards, and thus, no new risks to humans, animals, or the environment are anticipated" from the use of these techniques in animals, beyond those ...

Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer.

The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.

We recently published a list of Ark Invest Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other top ...